Equillium Inc (EQ)
NASDAQ:EQ
Top Page
Equillium
(NASDAQ:EQ)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▲(1.52% Upside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by weak financial performance (sharp 2025 revenue drop, persistent losses, and continued cash burn). Technicals are a notable positive with an improving uptrend and supportive momentum indicators, while valuation is constrained by negative earnings. The recent capital raise modestly improves runway but introduces potential dilution/overhang considerations.
Positive Factors
Extended Cash Runway
Combined year-end cash and the $35M financing materially extend operational runway into 2029 per management. This durable liquidity reduces short-term fundraising pressure, allowing multi-year clinical development of EQ504 and time to achieve value-driving milestones without urgent dilution.
Negative Factors
Severe Revenue Decline
A near-total revenue collapse indicates loss of prior commercial or partner-related inflows and severely weakens the ability to fund operations from internal cash generation. Sustained revenue volatility makes long-term planning and reinvestment riskier and increases reliance on external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended Cash Runway
Combined year-end cash and the $35M financing materially extend operational runway into 2029 per management. This durable liquidity reduces short-term fundraising pressure, allowing multi-year clinical development of EQ504 and time to achieve value-driving milestones without urgent dilution.
Read all positive factors
Equillium (EQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$124.56M
Dividend YieldN/A
Average Volume (3M)883.61K
Price to Earnings (P/E)―
Beta (1Y)-0.15
Revenue Growth-90.43%
EPS Growth-382.07%
CountryUS
Employees35
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding63,226,555
10 Day Avg. Volume862,141
30 Day Avg. Volume883,611
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)4.98
Price to Sales (P/S)1095.50
P/FCF Ratio-6.25
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-348.44
Enterprise Value/Ebitda-1.74
Forecast
1Y Price Target
$8.50Price Target Upside331.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.26
Revenue Forecast (FY)N/A
Equillium Business Overview & Revenue Model
Company Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001),...
How the Company Makes Money
Equillium does not have a broadly disclosed, established product-sales business model; as a clinical-stage biotech, it typically funds operations primarily through external financing rather than recurring commercial revenue. Material revenue, to t...
Equillium Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 130.00K | 41.09M | 36.08M | 15.76M | 0.00 |
| Gross Profit | 65.00K | 41.09M | 36.08M | 15.76M | -72.00K |
| EBITDA | -23.52M | -7.57M | -12.14M | -61.26M | -37.91M |
| Net Income | -22.40M | -8.07M | -13.34M | -62.43M | -38.98M |
Balance Sheet | |||||
| Total Assets | 31.89M | 25.60M | 50.53M | 78.42M | 85.41M |
| Cash, Cash Equivalents and Short-Term Investments | 30.28M | 22.57M | 40.87M | 71.02M | 80.71M |
| Total Debt | 719.00K | 384.00K | 824.00K | 10.19M | 11.79M |
| Total Liabilities | 3.29M | 6.54M | 27.96M | 46.48M | 18.90M |
| Stockholders Equity | 28.60M | 19.06M | 22.57M | 31.94M | 66.50M |
Cash Flow | |||||
| Free Cash Flow | -22.79M | -19.11M | -21.83M | -9.01M | -32.14M |
| Operating Cash Flow | -22.75M | -19.03M | -21.78M | -8.73M | -32.08M |
| Investing Cash Flow | 4.46M | 13.81M | -4.76M | 18.68M | 27.41M |
| Financing Cash Flow | 30.43M | 164.00K | -9.23M | -1.22M | 31.06M |
Equillium Technical Analysis
Neutral
1.97
Price Trends
1.77
Positive
1.45
Positive
1.26
Positive
Market Momentum
0.05
Positive
51.25
Neutral
62.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EQ, the sentiment is Neutral. The current price of 1.97 is below the 20-day moving average (MA) of 2.04, above the 50-day MA of 1.77, and above the 200-day MA of 1.26, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 51.25 is Neutral, neither overbought nor oversold. The STOCH value of 62.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EQ.
Equillium Risk Analysis
Equillium disclosed 82 risk factors in its most recent earnings report. Equillium reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Equillium Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $217.99M | -2.24 | -129.98% | ― | 250.00% | 15.15% | |
56 Neutral | $72.75M | -2.03 | 138.71% | ― | ― | -9.32% | |
52 Neutral | $124.56M | -6.36 | -119.19% | ― | -90.43% | -382.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $393.97M | -0.51 | 861.99% | ― | -34.36% | -59.98% | |
46 Neutral | $53.25M | -6.63 | -63.13% | ― | -17.94% | 21.43% |
* Healthcare Sector Average
EQ
Equillium
1.97
1.52
336.81%
NRXP
NRX Pharmaceuticals
2.20
0.39
21.55%
STRO
Sutro Biopharma
23.78
16.61
231.47%
HYFT
MindWalk Holdings
1.14
0.74
182.18%
PRLD
Prelude Therapeutics
3.46
2.81
432.31%
COEP
Coeptis Therapeutics Holdings
11.98
2.73
29.51%
Equillium Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Equillium Raises Capital Through Private Equity Securities Sale
Positive
Mar 13, 2026
On March 11, 2026, Equillium, Inc. entered into a securities purchase agreement with RA Capital Healthcare Fund, L.P. for a private placement of 1,179,508 common shares and a pre-funded warrant for up to 17,698,593 additional shares, priced off th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.